Sanofi-Aventis, Bristol-Myers Squibb win Plavix patent case

Share this article:

A federal judge today rejected a bid by generic drug maker Apotex to invalidate the patent of the blockbuster blood thinning drug Plavix, co-marketed by Sanofi-Aventis and Bristol-Myers Squibb.

“This court now finds that Apotex has failed to prove by clear and convincing evidence that the patent is invalid or unenforceable and Sanofi is entitled to a permanent injunction prohibiting Apotex from further infringement,” said US District Judge Sidney Stein, according to a published report.

Stein said he will determine damages in the case at a later date.
 
Last August, Stein stopped Apotex from selling its generic version of Plavix until he could hear the patent case. Apotex began selling its Plavix generic version last August after antitrust regulators rejected a proposed settlement in the case.

Sanofi-Aventis’ patent on Plavix expires in November 2011.

Plavix was the No. 2 selling drug behind Pfizer’s Lipitor in 2005, with global sales of $5.9 billion.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...